HJ SCIENCE-B

HJ Science Co., Ltd. engages in research and development of new small molecule drugs. The company focuses on metabolic diseases, oncology, and autoimmune disorders. The company’s core product pipeline includes HJ787, a selective TYK2 inhibitor intended for the treatment of atopic dermatitis (AD) and acne vulgaris (AV); HJ178, an orally available agent for type 2 diabetes; and HJ891, an oral KRAS inhibitor and intravenous injection intended for the treatment of non-small-cell lung cancer (NSCLC).